Agenus Inc. is a biopharmaceutical company focused on developing immunological therapies, primarily in oncology and autoimmune diseases. The company develops antibody-based product candidates, including checkpoint modulators and combination immunotherapies. Agenus seeks regulatory approval for its pipeline through clinical trials, and relies on collaborative arrangements and licensing agreements to advance its product candidates toward commercialization.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001193125-26-108632 | EDGAR | 100K words |
| 2025-03-17 | 2024-12-31 | 0000950170-25-040289 | EDGAR | 98K words |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031620 | EDGAR | 120K words |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008517 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001564590-22-007867 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001564590-21-013619 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001564590-20-011221 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001564590-19-008311 | EDGAR | — |
| 2018-03-16 | 2017-12-31 | 0001564590-18-006093 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001564590-17-004618 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-07 | 2026-06-30 | 0001193125-26-340363 | EDGAR | 27K words |
| 2025-11-10 | 2025-09-30 | 0001193125-25-274554 | EDGAR | 27K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106633 | EDGAR | 22K words |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069396 | EDGAR | 19K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125608 | EDGAR | 22K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093937 | EDGAR | 23K words |
| 2024-05-07 | 2024-03-31 | 0000950170-24-053951 | EDGAR | 17K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062051 | EDGAR | 22K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039768 | EDGAR | 20K words |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019649 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-022915 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001564590-22-028592 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-18 | 0001193125-26-355559 | EDGAR | 1K words |
| 2026-08-13 | 0001193125-26-347518 | EDGAR | 1K words |
| 2026-08-11 | 0001193125-26-344783 | EDGAR | 1K words |
| 2026-08-06 | 0001193125-26-336780 | EDGAR | 2K words |
| 2026-07-13 | 0001193125-26-301414 | EDGAR | 4K words |
| 2026-03-26 | 0001193125-26-125170 | EDGAR | 1K words |
| 2026-03-16 | 0001193125-26-107288 | EDGAR | 2K words |
| 2026-01-16 | 0001193125-26-014678 | EDGAR | 5K words |
| 2026-01-14 | 0001193125-26-012922 | EDGAR | 1K words |
| 2026-01-08 | 0001193125-26-007706 | EDGAR | 1K words |
267 total filings indexed. 235 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001098972 |
| Ticker | AGEN |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.agenusbio.com |
| Listed | 2000-02-04 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/AGEN (~200 tokens, structured JSON with cryptographic provenance)